New Survey Findings Highlight Gene Therapy Knowledge Gaps Among HCPs
NORD and FMC Illustrate Need for Increased Education and Awareness to Overcome Potential Treatment Barriers
Parsippany, NJ – April 16, 2020 – With the availability of several promising gene therapies and more on the horizon, a recent survey published in Neurology Reviews’ 6th annual Rare Neurological Disease Special Report indicates that many potential prescribers are unaware of the life-changing potential of gene therapy. The survey, a joint undertaking by the National Organization for Rare Disorders (NORD®) and Frontline Medical Communications (FMC), was completed by a representative sample of health care providers across a variety of specialties and practice settings. Nearly two-thirds of respondents (63%) were unaware of FDA-approved gene therapy options, such as Kymriah, Luxturna®, and Zolgensma®, and although respondents reported treating an average of five patients with a rare genetic disorder, few recognized the range of potential benefits of gene therapy, how it is administered, long-term impacts, and mechanisms by which it works.
A notable finding is the limited comfort level expressed by respondents in their knowledge base and ability to discuss genetic concepts with patients. Just 24% rated themselves as comfortable or extremely comfortable explaining somatic vs. germline mutations, and responses also identified unfamiliarity with gene delivery and administration options. The survey underscored the need for provider education on topics related to gene therapy, which is currently being seen as a potentially curative treatment for some rare disorders.
Concern that gene therapy will be cost-prohibitive (69%) and/or that patient access will be limited due to lack of insurance coverage (67%) ranked highly as perceived barriers.
“It is vital to develop strategies to ensure consistent and viable reimbursement models and to create multi-faceted, accessible educational outreach programs for the medical community at large,” said Katie Kowalski, Senior Program Manager of Educational Initiatives for NORD. “It is important for rare disease patients to be offered the opportunity to participate in clinical trials, and for clinicians to have accessible platforms to learn more about gene therapy so they can inform their patients about these treatment options.”
more recommended stories
Rare transplant aims to resolve woman’s long bout of cancer
UW Medicine team performs first-in-Pacific Northwest.
Organ transplant recipients can develop immunity after COVID-19, despite immunosuppression
Johns Hopkins Medicine researchers have shown.
Too many donor kidneys are discarded in U.S. before transplantation
When kidneys are removed from deceased.
In Light of Managing Bacterial Keratitis
Bacterial keratitis is an infection of.
Careful IOL selection needed in patients with retinal disease
When we perform cataract surgery for.
Surgical and drug treatment options lead to similar outcomes for diabetic eye disease
Surgical and injectable drug approaches are.
OMSs need research, now more than ever
A recent experience in the operating.
Coating implants with ‘artificial bone’ to prevent inflammation
Bone disease is becoming increasingly prevalent.
Researchers publish the first study on the metagenomics of dental black plaque in adults
The dark pigmentations that appear around.
Chronic pain can be devastating
Chronic pain can be devastating. You.